Search results
Results from the WOW.Com Content Network
Since its inception in 2000, TB Alliance has worked to grow the field of available treatments for TB and now manages the largest pipeline of new TB drugs in history. [1] It was founded in Cape Town, South Africa, and has since expanded. It is headquartered in New York City and has a regional office in Pretoria. [2]
Development of this compound was initiated because of the urgent need for new antibacterial drugs effective against resistant strains of tuberculosis. Also, current anti-TB drugs are mainly effective against replicating and metabolically active bacteria, creating a need for drugs effective against persisting or latent bacterial infections as ...
By gaining approval for a drug that treats a neglected disease, J&J is now able to request expedited FDA review of a future drug. [25] When it was approved by the FDA in December 2012, it was the first new medicine for TB in more than 40 years. [26] [27] In 2016, the WHO came under criticism for recommending it as an essential medicine. [28]
SQ109 showed activity against both drug susceptible and multi-drug-resistant tuberculosis bacteria, including extensively drug-resistant tuberculosis strains. In preclinical studies SQ109 enhanced the activity of anti-tubercular drugs isoniazid and rifampin and reduced by >30% the time required to cure mice of experimental TB.
In August 2022, plans for Phase II trials for a new tuberculosis treatment developed by PAN-TB were announced. [13] Gates MRI partnered with Merck Group in 2022 to further develop drugs to treat drug-resistant strains of TB. [16]
The Stop TB Initiative was established following the meeting of the First Session of the Ad Hoc Committee on the Tuberculosis Epidemic held in London in March 1998. [4] In March 2000 the Stop TB Partnership produced the Amsterdam Declaration to Stop TB, which called for action from ministerial delegations of 20 countries with the highest burden of TB.
The State TB Cell and the District TB Office govern the activities of the program at the state and district level respectively. At the sub-district/ Block level activities are organized under the Tuberculosis Unit (TB Unit). The Central TB Division is headed by a Deputy Director General - TB (DDG-TB) and is the National Program Manager.
Delamanid is sold under the brand name Deltyba, is a medication used to treat tuberculosis. [2] Specifically it is used, along with other antituberculosis medications, for active multidrug-resistant tuberculosis. [2] It is taken by mouth. [2] There are common side effects which include headache, dizziness, and nausea. [3]